Home > Boards > US OTC > Medical - Equipment >

Positron Corporation (POSC)

POSC RSS Feed
Add POSC Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/29/2022 3:21:50 AM - Followers: 166 - Board type: Free - Posts Today: 0

 



Symbol: OTC: POSC

Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.

Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source.  Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.

Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.

Key Business Components 
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology."  Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.

Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.


Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011).  Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
 
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).  
 
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging. 


Products
Attrius®
Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.

The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists.  This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists.
Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.

Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.


Positron is PET.

Company Website: http://www.positron.com

Share Structure
October 2017

Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979  Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares



Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.



DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.

POSC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#19490   Sometimes, I feel like I'm messaging myself but docteur/scanner 04/29/22 03:21:50 AM
#19489   All quiet on the boards and in the docteur/scanner 02/23/22 04:08:31 AM
#19488   Next Steps docteur/scanner 02/17/22 05:43:07 AM
#19487   Flurpiridaz F-18 is going to make cardiac PET zenvesting 02/08/22 12:05:20 PM
#19486   Apples, That is an impressive hold. docteur/scanner 02/08/22 06:13:28 AM
#19485   I can see a much higher value in aapples1992 02/06/22 05:43:50 PM
#19484   How about them Apples. Please stop telling people docteur/scanner 02/06/22 04:04:18 AM
#19483   $POSC going up much higher! Hold those shares aapples1992 02/05/22 09:05:12 AM
#19482   Nice Price action lately. Still holding a bunch aapples1992 02/05/22 08:48:23 AM
#19481   Medtrade77, Many thanks for that focus. I think docteur/scanner 02/03/22 05:48:49 AM
#19480   If anyone wants more insight to the focus Medtrade77 02/02/22 04:15:14 PM
#19479   I happen to agree with you on the docteur/scanner 02/02/22 11:42:45 AM
#19478   I do know enough about imaging to comment Medtrade77 02/02/22 09:21:33 AM
#19477   Medtrade77, As you are my go to guy docteur/scanner 02/01/22 10:28:29 AM
#19476   True it does trade as a private company. Medtrade77 01/31/22 11:44:06 AM
#19475   Medtrade , Many thanks for the response. That's docteur/scanner 01/28/22 02:57:08 AM
#19474   I know this because I inquired this a Medtrade77 01/27/22 05:28:57 PM
#19473   Dear All, I'm doing some research so if docteur/scanner 01/27/22 01:21:25 PM
#19472   Major game changer for Positron. Was expected as the Medtrade77 01/18/22 04:27:02 PM
#19471   6yr high closing price !!! Looks like dutchgold 01/03/22 10:09:35 PM
#19470   Wow So others catching on to this undervalued Medtrade77 01/03/22 05:38:45 PM
#19469   I love what I hear about this company. Once Medtrade77 12/21/21 01:41:02 PM
#19468   These guys are right it will be a Medtrade77 12/10/21 04:50:04 PM
#19467   The tailwinds are gusting, let's hope the company zenvesting 11/08/21 11:44:15 PM
#19466   Things are finally looking good here! aapples1992 11/01/21 11:04:07 AM
#19465   Great to hear of compliance. These guys are the Medtrade77 10/29/21 12:05:45 PM
#19464   Study: 18F-FES PET may help solve clinical dilemmas Medtrade77 10/04/21 09:44:15 PM
#19463   That's a succinct summary. I would just zenvesting 09/26/21 12:21:44 AM
#19462   POSC 4.4m float. 11th hour to get current. fink 09/24/21 02:41:40 PM
#19461   Cardiac PET predicts outcomes in aortic stenosis September 16, Medtrade77 09/20/21 04:08:18 PM
#19460   $POSC Positron Announces Timeline for Becoming Current with AskMuncher 09/18/21 10:39:12 AM
#19459   Yes F18 will be a major boost for Medtrade77 09/17/21 12:46:59 PM
#19458   Yes they need to begin making some sales, zenvesting 09/15/21 10:48:20 PM
#19457   Wow, just as stated. Without question we can expect Medtrade77 09/14/21 04:08:13 PM
#19456   Correct understanding the facts are important. Their public Medtrade77 09/13/21 12:01:17 PM
#19455   Well you seem to know more then me taxibabe 09/12/21 09:31:43 AM
#19454   I’m told until they get their financials posted Medtrade77 09/10/21 02:03:13 PM
#19453   How many are you trying to buy? taxibabe 09/08/21 12:33:00 PM
#19452   So difficult to buy shares. I don’t believe Medtrade77 09/07/21 06:57:43 PM
#19451   Yes no body doubts that PET is better taxibabe 08/17/21 11:15:10 AM
#19450   Yes no body doubts that PET is better taxibabe 08/17/21 11:06:10 AM
#19449   A study published in Surgery found 18F-fluorocholine positron Medtrade77 08/09/21 04:45:48 PM
#19448   Profits and dividends will be nice. Put in Medtrade77 08/02/21 11:01:37 PM
#19447   Its also the case that a lot of taxibabe 08/02/21 01:05:00 PM
#19446   If only the traders could look past what Medtrade77 08/02/21 10:15:38 AM
#19445   What updates? That story is getting long in taxibabe 07/30/21 02:37:12 PM
#19444   FCH-PET shines in guiding parathyroid surgery The study authors Medtrade77 07/28/21 03:48:45 PM
#19443   CMS removes exclusion for non-oncologic PET CMS published its Medtrade77 07/22/21 02:57:14 PM
#19442   Let’s all stay tuned for updates from the Jackers1 07/20/21 10:28:51 PM
#19441   Sounds like their getting ready to kill it. Medtrade77 07/20/21 05:58:40 PM
PostSubject
Consent Preferences